Salah M. Abdel-Aleem
Keine laufenden Positionen mehr
Profil
Salah M.
Abdel-Aleem joined Biopure Corp.
as Vice President of Clinical Research in August 2005.
He was Senior Clinical Manager of Peripheral Interventions for Guidant Corporation and held various clinical research management positions at A-Med, Inc., CardiacAssist, Inc., Biolectron, Inc. and U.S.
Surgical Corporation.
Dr. Abdel-aleem was Associate Director of Cardiac Metabolism Laboratory at the Duke University Medical Center and a Postdoctoral Fellow at Glaxo Pharmaceuticals.
He received a BS from Ain Shams University, an MS from Al Azhr University and a PhD from The City University of New York.
Ehemalige bekannte Positionen von Salah M. Abdel-Aleem
| Unternehmen | Position | Ende |
|---|---|---|
Biopure Corp.
 Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Salah M. Abdel-Aleem
| City University of New York | Doctorate Degree |
| Ain Shams University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
